PT  - JOURNAL ARTICLE
AU  - Manuel Weber
AU  - Claudia Kurek
AU  - Francesco Barbato
AU  - Matthias Eiber
AU  - Tobias Maurer
AU  - Michael Nader
AU  - Boris Hadaschik
AU  - Viktor Grünwald
AU  - Ken Herrmann
AU  - Axel Wetter
AU  - Wolfgang P. Fendler
TI  - PSMA-Ligand PET for Early Castration-Resistant Prostate Cancer: A Retrospective Single-Center Study
AID  - 10.2967/jnumed.120.245456
DP  - 2021 Jan 01
TA  - Journal of Nuclear Medicine
PG  - 88--91
VI  - 62
IP  - 1
4099  - http://jnm.snmjournals.org/content/62/1/88.short
4100  - http://jnm.snmjournals.org/content/62/1/88.full
SO  - J Nucl Med2021 Jan 01; 62
AB  - The low detection rate of conventional imaging and unspecific fluctuations in prostate-specific antigen can hamper early diagnosis of castration-resistant prostate cancer (CRPC). We thus assessed the value of prostate-specific membrane antigen (PSMA) PET/CT in the detection of early CRPC (prostate-specific antigen ≤ 3 ng/mL). Methods: We identified 55 patients with early CRPC from our institutional database. PSMA PET/CT and its CT component were interpreted independently by 3 masked readers. The primary endpoint was the per-patient detection rate; secondary endpoints were interobserver agreement and predictors of PET positivity. Results: PSMA PET/CT was positive in 41 of 55 (75%) patients. Sixteen of 55 (29%) patients had local disease only, and 25 of 55 (45%) had M1 disease. Overall, PSMA PET/CT interobserver agreement was substantial by Landis and Koch criteria (Fleiss κ = 0.77). Conclusion: PSMA PET/CT localized prostate cancer lesions in 75% of patients and M1 disease in 45%. Detection of early CRPC facilitates disease-delaying therapies for local or oligometastatic disease. PSMA PET/CT is of value in early CRPC and should be included in the CRPC entry criteria of the European Association of Urology and Prostate Cancer Working Group 3.